COMMUNIQUÉS West-GlobeNewswire

Oxford Healthspan to Introduce New Primeadine® GF Powder Through a ‘Longevity Shot’ Experience During Grammy Week in Los Angeles
31/01/2026
Science-Backed Spermidine Ritual Brings Cellular Renewal to a High-Performance Cultural Moment LOS ANGELES, Jan. 30, 2026 (GLOBE NEWSWIRE) -- As part of Grammy Week in Los Angeles, Oxford Healthspan will offer a preview [...]
Crescent Biopharma Announces Grants of Inducement Awards
30/01/2026
WALTHAM, Mass., Jan. 30, 2026 (GLOBE NEWSWIRE) -- Crescent Biopharma, Inc. (“Crescent” or the “Company”) (Nasdaq: CBIO), a clinical-stage biotechnology company dedicated to rapidly advancing the next wave of therapies [...]
Olema Oncology Announces Departure of Chief Operating and Financial Officer
30/01/2026
SAN FRANCISCO, Jan. 30, 2026 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema”, or “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and [...]
NurExone Appoints Eyal Gabbai to Board, Adding Large-Scale Healthcare System and Capital Markets Expertise
30/01/2026
Chairman of Meuhedet, Israel’s third-largest health fund TORONTO and HAIFA, Israel, Jan. 30, 2026 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) (FSE: J90) (“ NurExone ” or the “ Company ”) today [...]
Enzon Announces Commencement of Exchange Offer Relating to Series C Non-Convertible Redeemable Preferred Stock in Connection With Viskase Merger
30/01/2026
CRANFORD, N.J., Jan. 30, 2026 (GLOBE NEWSWIRE) -- Enzon Pharmaceuticals, Inc. (OTCQB: ENZN) (“Enzon” or the “Company”), today announced that it has commenced an exchange offer (the “Offer”) involving its Series C Non- [...]
Achieve Life Sciences Announced Granting of New Hire Inducement Awards
30/01/2026
SEATTLE and VANCOUVER, British Columbia, Jan. 30, 2026 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a late-stage specialty pharmaceutical company focused on the global development and [...]
Tevogen Board to Evaluate Potential One-Time Special Cash Dividend to Shareholders
30/01/2026
WARREN, N.J., Jan. 30, 2026 (GLOBE NEWSWIRE) -- Tevogen (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN ) today announced that its Board of Directors has expressed its intention to evaluate the potential [...]
Dr. Linette Williamson Expands Integrative Medicine Services in Encinitas With Physician-Supervised Ozone Sauna Therapy
30/01/2026
Encinitas, CA, Jan. 30, 2026 (GLOBE NEWSWIRE) -- Dr. Linette Williamson, MD, a physician with extensive experience in emergency medicine and integrative functional care, is expanding the therapeutic services offered at [...]
CrazyBulk: SARM Alternatives for Bulking, Strength and Performance or Just Hype?
30/01/2026
New York City, NY, Jan. 30, 2026 (GLOBE NEWSWIRE) -- Visit Official CrazyBulk Website Here TL;DR Summary: A lot of athletes, whether they are professionals or just training for personal goals, eventually hit a point [...]
OKYO Pharma Announces Acceptance of Urcosimod Phase 2 Study Results for Presentation at Prestigious ASCRS Annual Meeting
30/01/2026
LONDON and NEW YORK, Jan. 30, 2026 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (Nasdaq: OKYO ), a clinical-stage biopharmaceutical company developing investigational therapies for the treatment of neuropathic corneal pain ( [...]
Elevar Therapeutics Announces FDA Acceptance of New Drug Application Resubmission for Rivoceranib in Combination with Camrelizumab as a First-line Systemic Treatment for Unresectable Hepatocellular Carcinoma
30/01/2026
FDA sets PDUFA target action date of July 23, 2026 FORT LEE, N.J., Jan. 30, 2026 (GLOBE NEWSWIRE) -- Elevar Therapeutics, Inc., a majority-owned subsidiary of HLB Co., Ltd. and a fully integrated biopharmaceutical [...]
ProMIS Neurosciences Announces Up to $175 Million Private Placement Financing
30/01/2026
Extends cash runway into 2028 Proceeds expected to enable completion of ProMIS’ landmark Phase 1b AD study and support execution of key clinical milestones Blinded 6-month top-line data expected mid-2026; 12-month top- [...]
Tonix Pharmaceuticals Presented Phase 3 RESILIENT Data on TONMYA™ (Cyclobenzaprine HCl Sublingual Tablets) at the 2026 Non-Opioid Pain Therapeutics Summit
30/01/2026
TONMYA demonstrated significant reduction in fibromyalgia pain compared with placebo in the Phase 3 RESILIENT study Unique sublingual formulation designed for bedtime dosing bypasses first-pass metabolism, optimizing [...]
Communiqué de presse : Le CHMP recommande l'approbation du Rezurock de Sanofi dans l’UE pour le traitement de la maladie chronique du greffon contre l’hôte
30/01/2026
Le CHMP recommande l'approbation du Rezurock de Sanofi dans l’UE pour le traitement de la maladie chronique du greffon contre l’hôte La recommandation s’appuie sur les résultats de sécurité et d’efficacité de plusieurs [...]
Press Release: Sanofi’s Rezurock recommended for EU approval by the CHMP to treat chronic graft-vs-host disease
30/01/2026
Sanofi’s Rezurock recommended for EU approval by the CHMP to treat chronic graft-vs-host disease Recommendation supported by safety and efficacy results from several clinical studies and real-world evidence If approved [...]
Immunocore announces R&D leadership evolution
30/01/2026
Immunocore announces R&D leadership evolution Dr. David Berman will depart the Company Dr. Mohammed Dar, Chief Medical Officer, and Mark Moyer, Head of Regulatory Sciences, promoted to Executive Vice President roles [...]
Johnson & Johnson receives CHMP positive opinion for AKEEGA® (niraparib and abiraterone acetate dual action tablet) for the treatment of patients with metastatic hormone-sensitive prostate cancer (mHSPC) with BRCA1/2 mutations
30/01/2026
AMPLITUDE is the first clinical trial to evaluate potential therapies for patients with mHSPC and known HRR gene alterations, with positive results supporting the niraparib-based combination regimen as a new standard of [...]
Aligos Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
30/01/2026
SOUTH SAN FRANCISCO, Calif., Jan. 30, 2026 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS, “Aligos”, “Company”), a clinical stage biopharmaceutical company focused on improving patient outcomes through best [...]
Alterity Therapeutics: Appendix 4C – Q2 FY26 Quarterly Cash Flow Report & Corporate Update
30/01/2026
− Phase 2 Data Strengthened, Strong Cash Position, and Phase 3 Planning Well Advanced − Highlights Phase 2 data for ATH434 in Multiple System Atrophy (MSA) strengthened by additional analyses and multiple international [...]

Pages